drugset / Trial / NCT05642312
A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.
Timeline
- Start
- 2023-01-09
- Primary completion
- 2024-12-09
- Completion
- 2025-07-09
Outcome
Met primary endpoint
release “primary endpoint data demonstrating statistically significant superiority over sham in MEERKAT, though not in SANDCAT” gene.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vamikibart | Monoclonal antibody | — | Intravitreal |